ImmuCell CorporationICCCNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank86
3Y CAGR+108.7%
5Y CAGR+9.8%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
+108.7%/yr
vs +23.7%/yr prior
5Y CAGR
+9.8%/yr
Recent acceleration
Acceleration
+85.0pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | 17.13% | +325.4% |
| 2024 | 4.03% | +128.1% |
| 2023 | -14.33% | -860.4% |
| 2022 | 1.88% | -86.6% |
| 2021 | 14.02% | +30.5% |
| 2020 | 10.74% | +3.0% |
| 2019 | 10.43% | +1196.0% |
| 2018 | 0.81% | -87.7% |
| 2017 | 6.56% | -63.6% |
| 2016 | 18.05% | - |